A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy

Status unconfirmed · Phase 2

Conditions studied: Diabetic Neuropathy, Chemotherapy Induced Neuropathy, HIV Neuropathy, Trauma Induced Neuropathy

In brief

A clinical outcomes study measuring reduction in pain and numbness experienced in four types of peripheral neuropathy patients during 60 day administration of the an amino acid formulation.

Key facts

Study ID

NCT01537705

Run by

Targeted Medical Pharma

People needed

24

Starts

2012-03-01

Expected to finish

2012-07-01

Last updated by the study team

2012-02-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmation of peripheral neuropathy diagnosis from physician.
• Subjects able to read and understand English.
• Subjects willing to commit to all study visits for the duration of administration.
• Male and non-pregnant/lactating females, ages 18 to 75.

You may not qualify if…

• Subjects hospitalized within the last 30 days.
• History of nerve surgery.
• Currently taking other medical foods.
• Existing serious medical condition (i.e. severe heart, liver or kidney disease).
• Subjects with measured creatinine greater than 2.5, ALT or AST greater than three times normal.

Where it is running

• Gabriel Halperin DPM Inc — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.